Why is publication of negative clinical trial data important?
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2012 |
---|---|
Erschienen: |
2012 |
Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
---|---|
Enthalten in: |
British journal of pharmacology - 167(2012), 7 vom: Dez., Seite 1395-1398 |
Beteiligte Personen: |
Hayes, Ann [VerfasserIn] |
---|
BKL: |
---|
Umfang: |
3 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
OLC1906462623 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC1906462623 | ||
003 | DE-627 | ||
005 | 20230518100921.0 | ||
007 | tu | ||
008 | 121107s2012 xx ||||| 00| ||und c | ||
028 | 5 | 2 | |a sw121106_1 |
035 | |a (DE-627)OLC1906462623 | ||
035 | |a (DE-599)GBVOLC1906462623 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
082 | 0 | 4 | |a 610 |
084 | |a PHARM |2 fid | ||
084 | |a 44.38 |2 bkl | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Hayes, Ann |e verfasserin |4 aut | |
245 | 1 | 0 | |a Why is publication of negative clinical trial data important? |
264 | 1 | |c 2012 | |
300 | |a 3 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
700 | 1 | |a Hunter, Jackie |4 oth | |
773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d Oxford : Wiley-Blackwell, 1968 |g 167(2012), 7 vom: Dez., Seite 1395-1398 |w (DE-627)12926895X |w (DE-600)80081-8 |w (DE-576)014459388 |x 0007-1188 |7 nnns |
773 | 1 | 8 | |g volume:167 |g year:2012 |g number:7 |g month:12 |g pages:1395-1398 |g extent:3 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_55 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4219 | ||
936 | b | k | |a 44.38 |q AVZ |
936 | b | k | |a 44.40 |q AVZ |
951 | |a AR | ||
952 | |d 167 |j 2012 |e 7 |c 12 |h 1395-1398 |g 3 |